Uterine Cervical Neoplasms Clinical Trial
Official title:
Chemotherapy With Anlotinib in Advanced Cervical Cancer: A Prospective, Single-arm Study
STUDY HYPOTHESIS: The primary hypothesis is whether chemotherapy with Anlotinib improves overall survival in advanced cervical cancer. TRIAL DESIGN: The study is a prospective, single-arm, observational clinical study. The study will be performed on an intent-to-treat population. All the enrolled patients received chemotherapy with Anlotinib. PRIMARY ENDPOINT: Overall survival, defined as the observed length of life from entry into the study to death from any cause or the date of last contact.
Patients with advanced (metastatic, persistent, and recurrent) cervical cancer will be recruited from Zhongda Hospital. Only patients who treated with paclitaxel plus nedaplatin will be included in the analysis. All patients receive paclitaxel (135-175mg /m^2) and nedaplatin (100 mg/m^2) infusion on day 1, and then take Anlotinib 12mg/d orally on day 7-21, every 3 weeks. Once patients reached CR or PR, Anlotinib was continued on 12mg/d maintenance therapy until disease progression or unacceptable toxicity was noted. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03225443 -
Observation and Evaluation of Short-term Curative Effect of Local Advanced Cervical Cancer Treated With Particle Radiotherapy Versus Neoadjuvant Chemotherapy
|
N/A | |
| Recruiting |
NCT01373723 -
Economic Evaluation of Three Populational Screening Strategies for Cervical Cancer
|
N/A | |
| Terminated |
NCT01234480 -
Intended Use Study of the BD SurePath Plus™ Pap
|
||
| Terminated |
NCT01194609 -
A Pilot Study of Radiation-Immune Cell Combination Therapy in Cervical Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02808832 -
An HPV Vaccine Provider Intervention in Safety Net Clinics
|
N/A | |
| Terminated |
NCT01075412 -
FLT PET Imaging for Cervical Cancer
|
Phase 2 | |
| Completed |
NCT01014026 -
Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention
|
Phase 3 | |
| Completed |
NCT02865889 -
Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications
|
N/A | |
| Completed |
NCT00377845 -
Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear.
|
Phase 0 | |
| Recruiting |
NCT05531981 -
Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer
|
||
| Recruiting |
NCT05393440 -
First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer
|
Phase 1 | |
| Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
| Completed |
NCT02866006 -
Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02320578 -
2D Versus 3D Radical Laparoscopic Hysterectomy for Cervical Cancer: a Prospective Randomized Trial
|
N/A | |
| Completed |
NCT03270995 -
Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study
|
N/A | |
| Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
| Not yet recruiting |
NCT05065853 -
Urinary and Vaginal HPV Testing in Cervical Cancer Screening
|
||
| Completed |
NCT01231945 -
Low-Cost Molecular Cervical Cancer Screening Study
|
N/A | |
| Completed |
NCT01717391 -
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
|
Phase 2 | |
| Active, not recruiting |
NCT04947605 -
Epidemiological Landscape of Cervical Cancer in Latin America
|